-- 根據FactSet調查的分析師報告，百健（Biogen，股票代碼：BIIB）的平均評級為“增持”，平均目標價為213.68美元。 （報道北美、亞洲和歐洲主要銀行及研究機構的股票、商品和經濟研究。研究機構可透過以下連結聯絡我們：https://www..com/contact-us）
Price: $183.69, Change: $-4.19, Percent Change: -2.23%
Related Articles
Asia
Seatrium Concludes the Divestment of Tugboat Fleet
Seatrium (SGX:5E2) completed the divestment of a fleet of 17 tugboats, according to a Monday filing with the Singapore Exchange.The divestment is expected to deliver over SG$50 million in annualized cost savings.Shares of the specialized engineering solutions company were down over 2% in Monday trading.
$SGX:5E2
Asia
China Nuclear Engineering's Attributable Profit Slides 36% in 2025
China Nuclear Engineering's (SHA:601611) attributable profit fell 36% to 1.32 billion yuan in 2025 from 2.06 billion yuan in 2024, according to a Saturday filing with the Shanghai bourse.Earnings per share at the nuclear power company decreased 37% to 0.36 yuan from 0.57 yuan in the previous year.Operating revenue declined 10% year over year to 101.9 billion yuan from 113.5 billion yuan.Shares decreased 2% during the midday break on Monday.
$SHA:601611
Asia
Junzheng Energy & Chemical's Attributable Profit Rises 18% in 2025; Shares Rise 4%
Inner Mongolia Junzheng Energy & Chemical's (SHA:601216) attributable profit rose 18% to 3.32 billion yuan in 2025 from 2.80 billion yuan in 2024, according to a Saturday filing with the Shanghai bourse.Earnings per share at the chemical manufacturer increased to 0.3932 yuan from 0.3323 yuan in the previous year.Operating revenue stayed flat at 25.2 billion yuan.Shares increased 4% during the midday break on Monday.
$SHA:601216